Partnering A Survival Strategy For Cash-Strapped Companies
By Nuala Moran
Wednesday, October 23, 2002
LONDON - With the capital markets closed, partnering is the only route to survival for biotechnology companies running out of cash. But doing deals is getting harder, with more due diligence, less interest in platform technologies and early stage products, and little appetite for drugs with novel mechanisms of action. (BioWorld International)
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.